Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06949410 · ClinicalTrials.gov registry record · Phase 1
HER2 Vaccine for Locally Advanced Breast Cancer
A Phase 1 study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Pravin T.P Kaumaya.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06949410: Recruiting Phase 1 study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Pravin T.P Kaumaya.
NCT06949410 is a Phase 1 study of Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by Pravin T.P Kaumaya. The registered enrollment target is 36 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06949410, a Phase 1 study of Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by Pravin T.P Kaumaya.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Primary Outcome
Number of adverse events as assessed by the NCI CTCAE v. 5.0
Conditions Studied
Interventions
- DRUG HER2 Vaccine
Study Locations (1)
Indiana
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-03 |
| Est. Completion | 2030-03 |
| Phase | Phase 1 |
What NCT06949410 shows while recruiting
NCT06949410 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which HER2 Vaccine is the first listed.
NCT06949410 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06949410 about?
NCT06949410 is a clinical study titled "HER2 Vaccine for Locally Advanced Breast Cancer". The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
What is the current status of trial NCT06949410?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-03. Estimated completion is 2030-03.
What conditions does trial NCT06949410 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-positive Breast Cancer.
What interventions are being tested in trial NCT06949410?
The interventions under investigation include: HER2 Vaccine (DRUG).
Who is sponsoring clinical trial NCT06949410?
This trial is sponsored by Pravin T.P Kaumaya, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06949410 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06949410's enrollment target sits among peer trials
36 916th of 1224 higher than 304 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia